Tokyo, Sept. 29 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063082) titled 'Impact of erythromycin supply interruption on patients with bronchiectasis' on Sept. 28.
Study Type:
Observational
Primary Sponsor:
Institute - National Hospital Organization Kyoto Medical Center
Condition:
Condition - Non-cystic fibrosis bronchiectasis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the impact of discontinuation of erythromycin or switching to another macrolide due to erythromycin supply interruption on bronchiectasis exacerbations in patients with non-cystic fibrosis bronchiectasis who had received erythromycin for at least 12 months.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1.Age 20 years or older.
2.Diagnosis of non-cystic fibrosis bronchiectasis.
3.Treatment with erythromycin for at least 3 months.
4.Discontinuation of erythromycin or switching to another macrolide due to erythromycin supply interruption between July 2024 and August 2025.
Key exclusion criteria - 1.Patients who discontinued or changed erythromycin for reasons other than erythromycin supply interruption.
2.Patients receiving long-term antimicrobial therapy for an indication other than bronchiectasis.
3.Patients with less than 3 months of follow-up after erythromycin discontinuation or switching.
Target Size - 120
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 09 Month 15 Day
Anticipated trial start date - 2026 Year 09 Month 15 Day
Last follow-up date - 2028 Year 09 Month 14 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072184
Disclaimer: Curated by HT Syndication.
